BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 22246902)

  • 1. Tumor suppressor function of PGP9.5 is associated with epigenetic regulation in prostate cancer--novel predictor of biochemical recurrence after radical surgery.
    Mitsui Y; Shiina H; Hiraki M; Arichi N; Hiraoka T; Sumura M; Honda S; Yasumoto H; Igawa M
    Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):487-96. PubMed ID: 22246902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
    Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
    Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
    Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
    Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.
    Kristensen H; Haldrup C; Strand S; Mundbjerg K; Mortensen MM; Thorsen K; Ostenfeld MS; Wild PJ; Arsov C; Goering W; Visakorpi T; Egevad L; Lindberg J; Grönberg H; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Clin Cancer Res; 2014 Apr; 20(8):2169-81. PubMed ID: 24737792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation of Integrin α4 and E-Cadherin Genes in Human Prostate Cancer.
    Mostafavi-Pour Z; Kianpour S; Dehghani M; Mokarram P; Torabinejad S; Monabati A
    Pathol Oncol Res; 2015 Sep; 21(4):921-7. PubMed ID: 25743258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
    Sørensen KD; Borre M; Ørntoft TF; Dyrskjøt L; Tørring N
    Int J Cancer; 2008 Feb; 122(3):509-19. PubMed ID: 17943724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypomethylation of the protein gene product 9.5 promoter region in gallbladder cancer and its relationship with clinicopathological features.
    Lee YM; Lee JY; Kim MJ; Bae HI; Park JY; Kim SG; Kim DS
    Cancer Sci; 2006 Nov; 97(11):1205-10. PubMed ID: 16965602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia.
    Paradowska A; Fenic I; Konrad L; Sturm K; Wagenlehner F; Weidner W; Steger K
    Int J Oncol; 2009 Jul; 35(1):87-96. PubMed ID: 19513555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
    Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
    Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
    Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
    Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
    Zhao H; Shiina H; Greene KL; Li LC; Tanaka Y; Kishi H; Igawa M; Kane CJ; Carroll P; Dahiya R
    Cancer; 2005 Jul; 104(1):44-52. PubMed ID: 15895377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
    Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
    BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.
    Lee J; Lee MS; Jeoung DI; Kim YM; Lee H
    Prostate; 2017 Mar; 77(4):350-360. PubMed ID: 27813113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
    Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
    Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
    Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
    Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
    Pulukuri SM; Rao JS
    Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma.
    Nojima D; Li LC; Dharia A; Perinchery G; Ribeiro-Filho L; Yen TS; Dahiya R
    Cancer; 2001 Oct; 92(8):2076-83. PubMed ID: 11596023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional role and tobacco smoking effects on methylation of CYP1A1 gene in prostate cancer.
    Mitsui Y; Chang I; Kato T; Hashimoto Y; Yamamura S; Fukuhara S; Wong DK; Shiina M; Imai-Sumida M; Majid S; Saini S; Shiina H; Nakajima K; Deng G; Dahiya R; Tanaka Y
    Oncotarget; 2016 Aug; 7(31):49107-49121. PubMed ID: 27203547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.